ALK and RET fusions were found to be associated with low responses to ICI while BRAF, KRAS, and c-MET alterations were associated with responses that were comparable to non-mutant NSCLC, and PD-L1 positive KRAS mutant NSCLC may be associated with better outcome when treated with ICI monotherapy as suggested by two retrospective studies. This evidence concerns the gene KRAS and non-small cell lung carcinoma.